BA
KURA icon

BlackRock Advisors’s Kura Oncology KURA Stock Holding History

BlackRock Advisors’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-768
Closed -$2K – 3736
2016
Q2 		$2K Sell
768
-495
-39% -$1.54K ﹤0.01% 3714
2016
Q1 		$5K Buy
+1,263
New +$5.99K ﹤0.01% 3666

Other funds holding KURA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
CCP
Clough Capital Partners Boston, Massachusetts $1.04B AUM 49.7% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MA
Minerva Advisors Bala Cynwyd, Pennsylvania $155M AUM 35.49% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

BlackRock Advisors's KURA Position: Q3 2016 in Review

BlackRock Advisors sold out of Kura Oncology (KURA) in Q3 2016, closing a stake of 768 shares — an estimated $2K sold.

BlackRock Advisors first reported a position in KURA in Q1 2016 and held it in 2 quarters. The position peaked at $5K in Q1 2016. 28 funds tracked by Wall St. Rank hold KURA as of Q3 2016.

  • BlackRock Advisors reported no remaining Kura Oncology position as of Q3 2016 after selling out during the quarter.
  • BlackRock Advisors sold 768 Kura Oncology shares in Q3 2016, an estimated $2K.
  • BlackRock Advisors first reported a position in Kura Oncology in Q1 2016 and held it in 2 quarters.
  • BlackRock Advisors's Kura Oncology position peaked at $5K in Q1 2016.
  • 28 funds tracked by Wall St. Rank held Kura Oncology as of Q3 2016.

Based on BlackRock Advisors's 13F filing for Q3 2016, filed 8 Nov 2016.